FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications”

Mohammad Akbar, Erin Berry-Bibee, Diana L. Blithe, Ruth S. Day, Alison Edelman, Joachim Höchel, Roxanne Jamshidi, Myong Jin Kim, Li Li, Vivek S. Purohit, Jim A. Turpin, Pamela E. Scott, David G. Strauss, Haiying Sun, Naomi K. Tepper, Lei Zhang, Chongwoo Yu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Potential drug interactions with hormonal contraceptives are an important public health concern. A public meeting on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implication” was hosted by the United States Food and Drug Administration (FDA). The meeting endeavored to provide an opportunity for the FDA to seek input from experts on the public health concerns associated with the use of hormonal contraceptives and interacting drugs that might affect efficacy and safety, including pharmacokinetic/pharmacodynamic considerations, in the design of drug interaction studies of hormonal contraceptives for drug development and approaches to translating the results of drug interaction information into informative labeling and communication. The input received could be used to refine FDA's thinking on hormonal contraceptives drug interaction study design and interpretation and labeling communication of drug interaction risk. This meeting benefited from strong and diverse participation from the Center for Drug Evaluation and Research at the FDA, Centers for Disease Control and Prevention, National Institutes of Health, Swedish Medical Products Agency, pharmaceutical industry, and representatives of academia. This report provides a summary of the key discussion based on the presentations and panel discussion.

Original languageEnglish (US)
JournalJournal of Clinical Pharmacology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

United States Food and Drug Administration
Contraceptive Agents
Drug Interactions
Public Health
Pharmaceutical Preparations
Drug Evaluation
National Institutes of Health (U.S.)
Drug Industry
Centers for Disease Control and Prevention (U.S.)
Pharmacokinetics
Safety

Keywords

  • drug development
  • drug interaction
  • hormonal contraceptive
  • labeling and communication

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives : Public Health and Drug Development Implications”. / Akbar, Mohammad; Berry-Bibee, Erin; Blithe, Diana L.; Day, Ruth S.; Edelman, Alison; Höchel, Joachim; Jamshidi, Roxanne; Kim, Myong Jin; Li, Li; Purohit, Vivek S.; Turpin, Jim A.; Scott, Pamela E.; Strauss, David G.; Sun, Haiying; Tepper, Naomi K.; Zhang, Lei; Yu, Chongwoo.

In: Journal of Clinical Pharmacology, 01.01.2018.

Research output: Contribution to journalArticle

Akbar, M, Berry-Bibee, E, Blithe, DL, Day, RS, Edelman, A, Höchel, J, Jamshidi, R, Kim, MJ, Li, L, Purohit, VS, Turpin, JA, Scott, PE, Strauss, DG, Sun, H, Tepper, NK, Zhang, L & Yu, C 2018, 'FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications”', Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.1285
Akbar, Mohammad ; Berry-Bibee, Erin ; Blithe, Diana L. ; Day, Ruth S. ; Edelman, Alison ; Höchel, Joachim ; Jamshidi, Roxanne ; Kim, Myong Jin ; Li, Li ; Purohit, Vivek S. ; Turpin, Jim A. ; Scott, Pamela E. ; Strauss, David G. ; Sun, Haiying ; Tepper, Naomi K. ; Zhang, Lei ; Yu, Chongwoo. / FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives : Public Health and Drug Development Implications”. In: Journal of Clinical Pharmacology. 2018.
@article{e2e483dbc9e5424ba0c6e595267d9c6b,
title = "FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications”",
abstract = "Potential drug interactions with hormonal contraceptives are an important public health concern. A public meeting on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implication” was hosted by the United States Food and Drug Administration (FDA). The meeting endeavored to provide an opportunity for the FDA to seek input from experts on the public health concerns associated with the use of hormonal contraceptives and interacting drugs that might affect efficacy and safety, including pharmacokinetic/pharmacodynamic considerations, in the design of drug interaction studies of hormonal contraceptives for drug development and approaches to translating the results of drug interaction information into informative labeling and communication. The input received could be used to refine FDA's thinking on hormonal contraceptives drug interaction study design and interpretation and labeling communication of drug interaction risk. This meeting benefited from strong and diverse participation from the Center for Drug Evaluation and Research at the FDA, Centers for Disease Control and Prevention, National Institutes of Health, Swedish Medical Products Agency, pharmaceutical industry, and representatives of academia. This report provides a summary of the key discussion based on the presentations and panel discussion.",
keywords = "drug development, drug interaction, hormonal contraceptive, labeling and communication",
author = "Mohammad Akbar and Erin Berry-Bibee and Blithe, {Diana L.} and Day, {Ruth S.} and Alison Edelman and Joachim H{\"o}chel and Roxanne Jamshidi and Kim, {Myong Jin} and Li Li and Purohit, {Vivek S.} and Turpin, {Jim A.} and Scott, {Pamela E.} and Strauss, {David G.} and Haiying Sun and Tepper, {Naomi K.} and Lei Zhang and Chongwoo Yu",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jcph.1285",
language = "English (US)",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives

T2 - Public Health and Drug Development Implications”

AU - Akbar, Mohammad

AU - Berry-Bibee, Erin

AU - Blithe, Diana L.

AU - Day, Ruth S.

AU - Edelman, Alison

AU - Höchel, Joachim

AU - Jamshidi, Roxanne

AU - Kim, Myong Jin

AU - Li, Li

AU - Purohit, Vivek S.

AU - Turpin, Jim A.

AU - Scott, Pamela E.

AU - Strauss, David G.

AU - Sun, Haiying

AU - Tepper, Naomi K.

AU - Zhang, Lei

AU - Yu, Chongwoo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Potential drug interactions with hormonal contraceptives are an important public health concern. A public meeting on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implication” was hosted by the United States Food and Drug Administration (FDA). The meeting endeavored to provide an opportunity for the FDA to seek input from experts on the public health concerns associated with the use of hormonal contraceptives and interacting drugs that might affect efficacy and safety, including pharmacokinetic/pharmacodynamic considerations, in the design of drug interaction studies of hormonal contraceptives for drug development and approaches to translating the results of drug interaction information into informative labeling and communication. The input received could be used to refine FDA's thinking on hormonal contraceptives drug interaction study design and interpretation and labeling communication of drug interaction risk. This meeting benefited from strong and diverse participation from the Center for Drug Evaluation and Research at the FDA, Centers for Disease Control and Prevention, National Institutes of Health, Swedish Medical Products Agency, pharmaceutical industry, and representatives of academia. This report provides a summary of the key discussion based on the presentations and panel discussion.

AB - Potential drug interactions with hormonal contraceptives are an important public health concern. A public meeting on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implication” was hosted by the United States Food and Drug Administration (FDA). The meeting endeavored to provide an opportunity for the FDA to seek input from experts on the public health concerns associated with the use of hormonal contraceptives and interacting drugs that might affect efficacy and safety, including pharmacokinetic/pharmacodynamic considerations, in the design of drug interaction studies of hormonal contraceptives for drug development and approaches to translating the results of drug interaction information into informative labeling and communication. The input received could be used to refine FDA's thinking on hormonal contraceptives drug interaction study design and interpretation and labeling communication of drug interaction risk. This meeting benefited from strong and diverse participation from the Center for Drug Evaluation and Research at the FDA, Centers for Disease Control and Prevention, National Institutes of Health, Swedish Medical Products Agency, pharmaceutical industry, and representatives of academia. This report provides a summary of the key discussion based on the presentations and panel discussion.

KW - drug development

KW - drug interaction

KW - hormonal contraceptive

KW - labeling and communication

UR - http://www.scopus.com/inward/record.url?scp=85053208189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053208189&partnerID=8YFLogxK

U2 - 10.1002/jcph.1285

DO - 10.1002/jcph.1285

M3 - Article

C2 - 30144093

AN - SCOPUS:85053208189

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -